ACTUATE THERAPEUTICS, INC.
Close on Oct 19, 2026
- Market cap
- $14.30M
- P/E (TTM)
- –
- Dividend yield
- –
About Actuate Therapeutics
Pharmaceutical Preparations, SIC 2834
Actuate Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing therapies for difficult-to-treat cancers by inhibiting glycogen synthase kinase-3 beta (GSK-3β). The company centers its research and development on its lead small-molecule product candidate, elraglusib, which functions by blocking signaling pathways essential for cancer cell survival and tumor growth while also regulating anti-tumor immunity. Actuate develops elraglusib across two primary delivery formulations, including an intravenous injection and an oral tablet. Its investigational treatments aim to address adult and pediatric patient populations facing complex oncological conditions such as metastatic pancreatic ductal adenocarcinoma, pediatric refractory solid tumors including Ewing sarcoma and neuroblastoma, metastatic melanoma, and colorectal cancer.
The company operates as a clinical-stage organization with clinical trials evaluating treatments in hundreds of patients. Actuate maintains principal executive offices in Fort Worth, Texas.
Summary of the business section of Actuate Therapeutics's latest annual report, written by StockData.
Company profile
Company
- Legal name
- ACTUATE THERAPEUTICS, INC.
- Headquarters
- Fort Worth, TX
- Address
- 1751 River Run, Suite 400 76107
- Phone
- (847) 986-4190
- Website
- actuatetherapeutics.com
- Employees
- 12, Dec 31, 2025
- Industry
- Pharmaceutical Preparations
- Incorporated in
- Delaware
- Fiscal year ends
- December 31
- Auditor
- Crowe LLP, Costa Mesa, California
Stock & identifiers
- Ticker
- ACTU
- Exchange
- Nasdaq
- IPO date
- Aug 13, 2024
- Shares outstanding
- 24M, Aug 13, 2026
- Public float
- $42.10M, Jun 30, 2025
- Filer category
- Non-accelerated filer<br>Smaller reporting company<br>Emerging growth company
- SEC CIK
- 1652935
- CUSIP
- 005083100
- ISIN
- US0050831009
- EIN
- 47-3044785
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| Daniel M. Schmitt | President, CEO and Director | 1,052,977 |
| Andrew Paul Mazar | Chief Operating Officer | 127,250 |
| Paul J. Lytle | Chief Financial Officer | – |
| Martin H. Huber Jr. | Director | – |
| Amy L. Ronneberg | Director | – |
| Roger Sawhney | Director | – |
| Jason A. Keyes | Director | – |
| Todd S. Thomson | Director | 2,354,344 |
| Aaron G.L. Fletcher | Director | – |
| Dan Zabrowski | Director | 76,348 |
| Kairos Venture Partners II, L.P. | Director | – |
| BIOS Advisors GP, LLC | Director | – |
| BIOS Fund II QP, LP | Director | 9,147,214 |
| BIOS Fund II NT, LP | Director | – |
| BIOS Equity Partners III, LP | Director | 9,895,975 |
| BIOS Fund III, LP | Director | – |
| BIOS Fund III QP, LP | Director | – |
| BIOS Fund III NT, LP | Director | – |
| Bios Equity COF, LP | Director | 10,196,456 |
| Bios Clinical Opportunity Fund, LP | Director | 1,472,797 |
| BIOS Actuate Co-Invest II, LP | Director | – |
| Bios Actuate Co-Invest III, LP | Director | 231,377 |
| BIOS Actuate Co-Invest I, LP | Director | 10,196,456 |
| Bios 2024 Co-Invest, LP | Director | 125,000 |
| Leslie W. Kreis | Director | – |
Employees
Headcount reported in annual reports
“we had 12 full-time employees plus a number of contract workers, who manage and oversee all aspects of our operations, including”
Corporate history
Events identified from SEC filings
| Date | Event | Details |
|---|---|---|
| Jul 17, 2026 | Listing notice | Notice of delisting or failure to satisfy a listing rule (8-K Item 3.01) |
| Aug 19, 2024 | Auditor change | Change in certifying accountant (8-K Item 4.01) |
| Aug 13, 2024 | IPO | Initial public offering priced (424B4 prospectus) |
| Jun 20, 2024 | Listing | Registration of securities on an exchange (Form 8-A) |